The Differences in Adjuvant Therapy Effectiveness Meloxicam and N-Acetylcysteine against Negative Symptoms of Schizophrenia
Downloads
Highlights:
1. Schizophrenic patients can have negative symptoms.
2. Adjuvant therapy is needed to assist antipsychotics in reducing the negative symptoms of schizophrenic patients.
Abstract
Introduction: Meloxicam and N-Acetylcysteine are examples of drugs with anti-inflammatory effects that have been widely studied, and are considered to reduce negative symptoms of schizophrenia. Both of these drugs are also widely available in Indonesia and can be obtained at an affordable price. This study aimed to analyze the differences in the effectiveness of adjuvant therapy meloxicam and N-Acetylcysteine on negative symptoms of schizophrenic patients.
Methods: This was a quasi-experimental study using a single-blind, pretest–post-test design. Determination of the subject used a purposive sampling technique according to the inclusion criteria. This study examined 34 samples and divided them into two groups. In group A, 17 subjects received adjuvant meloxicam therapy of 15 mg/day for 4 weeks; in group B, 17 subjects received adjuvant therapy of N-Acetylcysteine 400 mg/day for 4 weeks. Score assessment was performed using the positive scale, negative scale, and general psychopathology scale (PANSS) negative subscale pre- and post-therapy, then compared the effectiveness. Data analysis used SPSS 25.0.
Results: The mean score of the PANSS post-test subscale was negative in the meloxicam adjuvant therapy group 15.58, while for the N-Acetylcysteine adjuvant therapy group was 17.64 with a p-value of 0.009. The mean decrease in the negative subscale PANSS score in the meloxicam adjuvant therapy group was 11.00, while the N-Acetylcysteine adjuvant therapy group was 19.70 with a p-value of 0.000.
Conclusion: There was no difference in the effectiveness of adjuvant therapy meloxicam and N-Acetylcysteine in improving negative symptoms of schizophrenic patients.
Jingping Z, Lulu Z. The Importance of Early Identification and Treatment in Negative Symptoms of Schizophrenia. Chinese J Psychiatry 2015; 1–3.
Saputra CAH. Gambaran Ekspetasi dan Harapan Pasien Schizophrenia terhadap Pelayanan Terapi Aktivitas Kelompok di Rumah Sakit Jiwa Daerah Dr. Arif Zainudin Surakarta. Universitas Muhammadiyah Surakarta, https://eprints.ums.ac.id/93772/1/NASKAH PUBLIKASI.pdf (2021).
Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in Schizophrenia Especially Focused on the Role of Microglia. Prog Neuro-Psychopharmacology Biol Psychiatry 2013; 42: 115–121.
Lolobua MFIP, Khairina K, Wardani IAK, et al. Negative Symptoms Management in Schizophrenia. J Psikiatri Surabaya 2021; 10: 6–12.
Syulthoni ZB, Gunadi IGN. Cognitive Enhancement Therapy in Schizophrenia. J Psikiatri Surabaya 2020; 9: 7–13.
Fitryasari R, Nursalam N, Yusuf A, et al. Development of a Family Resiliency Model to Care of Patients with Schizophrenia. Scand J Caring Sci 2021; 35: 642–649.
Jessica L, Fithriyah I, Ardani IGAI. The Importance of Family Support in Successful Treatment Adherence of Schizophrenic Patient. J Psikiatri Surabaya 2021; 10: 83–91.
Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat 2020; 16: 519–534.
Kirschner M, Aleman A, Kaiser S. Secondary Negative Symptoms ” A Review of Mechanisms, Assessment and Treatment. Schizophr Res 2017; 186: 29–38.
Sarkar S, Hillner K, Velligan DI. Conceptualization and Treatment of Negative Symptoms in Schizophrenia. World J Psychiatry 2015; 5: 352–361.
Na K-S, Jung H-Y, Kim Y-K. The Role of Pro-Inflammatory Cytokines in the Neuroinflammation and Neurogenesis of Schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 277–286.
Paul-Samojedny M, Owczarek A, Kowalczyk M, et al. Association of Interleukin 2 (IL-2), Interleukin 6 (IL-6), and TNF-Alpha (TNFα) Gene Polymorphisms with Paranoid Schizophrenia in a Polish Population. J Neuropsychiatry Clin Neurosci 2013; 25: 72–82.
Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine Function in Medication-Naive First Episode Psychosis: A Systematic Review and Meta-Analysis. Schizophr Res 2014; 155: 101–108.
Zheng W, Cai D-B, Yang X-H, et al. Adjunctive Celecoxib for Schizophrenia: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. J Psychiatr Res 2017; 92: 139–146.
Yolland CO, Hanratty D, Neill E, et al. Meta-Analysis of Randomised Controlled Trials with N-Acetylcysteine in the Treatment of Schizophrenia. Aust N Z J Psychiatry 2020; 54: 453–466.
Cho M, Lee TY, Kwak Y Bin, et al. Adjunctive Use of Anti-Inflammatory Drugs for Schizophrenia: A Meta-Analytic Investigation of Randomized Controlled Trials. Aust N Z J Psychiatry 2019; 53: 742–759.
Furlong NE, Lovelace EA, Lovelace KL. Research Methods and Statistics: An Integrated Approach. Harcourt College Publishers, https://books.google.co.id/books?id=RyGaQgAACAAJ (2000).
Purwono H. Pengaruh Pemberian Terapi Tambahan Meloxicam terhadap Kadar Hs-CRP dan Skor PANSS pada Pasien Skizofrenia di RSJD Arif Zainudin Surakarta. Universitas Sebelas Maret, https://digilib.uns.ac.id/dokumen/detail/58379/Pengaruh-Pemberian-Terapi-Tambahan-Meloxicam-terhadap-Kadar-Hs-Crp-dan-Skor-Panss-pada-Pasien-Skizofrenia-di-Rsjd-Arif-Zainudin-Surakarta (2018).
Sepehrmanesh Z, Heidary M, Akasheh N, et al. Therapeutic Effect of Adjunctive N-Acetyl Cysteine (NAC) on Symptoms of Chronic Schizophrenia: A Double-Blind, Randomized Clinical Trial. Prog Neuropsychopharmacol Biol Psychiatry 2018; 82: 289–296.
Arisyna A, Sustini F, Muhdi N. Anxiety Level and Risk Factors in Medical Students. JUXTA J Ilm Mhs Kedokt Univ Airlangga 2020; 11: 79–82.
Choi S-H, Aid S, Bosetti F. The Distinct Roles of Cyclooxygenase-1 and -2 in Neuroinflammation: Implications for Translational Research. Trends Pharmacol Sci 2009; 30: 174–181.
Prieto A, De Barrio M, Martín E, et al. Tolerability to Nabumetone and Meloxicam in Patients with Nonsteroidal Anti-Inflammatory Drug Intolerance. J Allergy Clin Immunol 2007; 119: 960–964.
Kotilinek LA, Westerman MA, Wang Q, et al. Cyclooxygenase-2 Inhibition Improves Amyloid-Beta-Mediated Suppression of Memory and Synaptic Plasticity. Brain 2008; 131: 651–664.
Müller N, Schwarz MJ. A Psychoneuroimmunological Perspective to Emil Kraepelins Dichotomy: Schizophrenia and Major Depression as Inflammatory CNS Disorders. Eur Arch Psychiatry Clin Neurosci 2008; 258 Suppl: 97–106.
Müller N, Riedel M, Schwarz MJ. Psychotropic Effects of COX-2 Inhibitors--A Possible New Approach for the Treatment of Psychiatric Disorders. Pharmacopsychiatry 2004; 37: 266–269.
Wilmana P, Gunawan SG. Analgesik-Antipiretik, Analgesik Antiinflamasi Nonsteroid, dan Obat Gangguan Sendi Lainnya. In: Farmakologi dan Terapi. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia, 2012, pp. 230–246.
Katzung BG. Basic and Clinical Pharmacology. 10th ed. Jakarta: EGC Medical Book Publisher, 2010.
Hashimoto K, Tsukada H, Nishiyama S, et al. Protective Effects of N-Acetyl-L-Cysteine on the Reduction of Dopamine Ttransporters in the Striatum of Monkeys Treated with Methamphetamine. Neuropsychopharmacology 2004; 29: 2018–2023.
Steullet P, Neijt HC, Cuénod M, et al. Synaptic Plasticity Impairment and Hypofunction of NMDA Receptors Induced by Glutathione Deficit: Relevance to Schizophrenia. Neuroscience 2006; 137: 807–819.
Grant JE, Odlaug BL, Kim SW. N-Acetylcysteine, a Glutamate Modulator, in the Treatment of Trichotillomania: A Double-Blind, Placebo-Controlled Study. Arch Gen Psychiatry 2009; 66: 756–763.
Kigerl A. Routine Activity Theory and the Determinants of High Cybercrime Countries. Soc Sci Comput Rev 2011; 30: 470–486.
Ooi SL, Green R, Pak SC. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. Biomed Res Int 2018; 2018: 2469486.
Breier A, Liffick E, Hummer TA, et al. Effects of 12-Month, Double-Blind N-Acetyl Cysteine on Symptoms, Cognition and Brain Morphology in Early Phase Schizophrenia Spectrum Disorders. Schizophr Res 2018; 199: 395–402.
Salsabila KN, Khairina K, Djuari L. Profile of Chronic Mental Disorder Patients with or without Suicide Ideation in the Psychiatric Ward of Dr. Soetomo General Hospital, Surabaya. JUXTA J Ilm Mhs Kedokt Univ Airlangga 2021; 12: 48–53.
Hans D, Rengel A, Hans J, et al. N-Acetylcysteine as a Novel Rapidly Acting Anti-Suicidal Agent: A Pilot Naturalistic Study in the Emergency Setting. PLoS One 2022; 17: e0263149.
Willborn RJ, Hall CP, Fuller MA. Recycling N-Acetylcysteine: A Review of Evidence for Adjunctive Therapy in Schizophrenia. Ment Heal Clin 2019; 9: 116–123.
Davis J, Moylan S, Harvey BH, et al. Neuroprogression in Schizophrenia: Pathways Underpinning Clinical Staging and Therapeutic Corollaries. Aust N Z J Psychiatry 2014; 48: 512–529.
Robertson OD, Coronado NG, Sethi R, et al. Putative Neuroprotective Pharmacotherapies to Target the Staged Progression of Mental Illness. Early Interv Psychiatry 2019; 13: 1032–1049.
Bradlow RCJ, Berk M, Kalivas PW, et al. The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. CNS Drugs 2022; 36: 451–482.
Davis J, Eyre H, Jacka FN, et al. A Review of Vulnerability and Risks for Schizophrenia: Beyond the Two Hit Hypothesis. Neurosci Biobehav Rev 2016; 65: 185–194.
Chong HY, Teoh SL, Wu DB-C, et al. Global Economic Burden of Schizophrenia: A Systematic Review. Neuropsychiatr Dis Treat 2016; 12: 357–373.
Copyright (c) 2023 Banu Kadgada Kalingga Murda, I Gusti Bagus Indro Nugroho, Adriesti Herdaetha
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The formal legal aspect of journal publication accessibility refers to Creative Commons Atribution-Share Alike 4.0 (CC BY-SA).
